KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2005.04

  -

  Present

  Department of Neurology, Keio University School of Medicine

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 2002.04

  -

  2006.03

  Keio University School of Medicine, Medicine

  Graduate School, Withdrawal after completion of doctoral course requirements

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 医学, Keio University, Coursework, 2009.01

  新規カルシウム結合蛋白Iba 1の脳内局在.

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• medical license, 2002.05

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Neurology

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• Neurology

Research Themes 【 Display / hide 】

Research Themes 【 Display / hide 】

• Neurology, 

  2002.04

  -

  Present

Books 【 Display / hide 】

Books 【 Display / hide 】

• Dementia

  伊東大介, 講談社, 2017.11,  Page： 208

  　View Summary

  2015年の厚生労働省の発表によると10年後には認知症患者数は700万人にのぼり、高齢者の5人に1人が認知症である計算になる。日本の人口構成の高齢化に伴い増加する認知症の医療と対策は、21世紀の避けられない重大な課題である。このような社会的状況を見据え、慶應義塾大学病院では、神経内科および精神・神経科の２診療科合同で、平成20年より認知症診療に特化した専門外来「メモリー外来」を開設している。
  本書は、10年近くになるメモリー外来での診療を踏まえ、患者様、ご家族の方からの実際の声をもとにした一般向けの認知症解説書である。認知症のメカニズムから、予防、診断治療そして介護に至るまで専門医の立場からに平易に説明している。
  近年、分子PETイメージングの発展により、アルツハイマー病では認知障害が顕在化する約20年前から病因であるベーターアミロイドの蓄積が先行していることが分かってきてた。すなわち、働き盛りの４０-５０代から脳の病理異常が始まっている人がいる。この状態は物忘れが出るまえのアルツハイマー病という意味で「プレクリニカル・アルツハイマー病（本書ではプレクリニカル認知症と記載）」と呼ばれ、アルツハイマー病の予防対象として注目されている。本書では、この新しい概念であるプレクリニカル認知症について概説し、中年期からの認知症予防の重要性を強調している。
  
  

• 細胞工学　アルツハイマー病の根本治療への展望

  ITO DAISUKE, 学研メディカル秀潤社, 2012

• メモリークリニック診療マニュアル

  ITO DAISUKE, 南江堂, 2011

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings

  Iwabuchi Y., Nakahara T., Kameyama M., Yamada Y., Hashimoto M., Matsusaka Y., Osada T., Ito D., Tabuchi H., Jinzaki M.

  EJNMMI Research (EJNMMI Research)  9 2019

  　View Summary

  © 2019, The Author(s). Background: We sought to assess the machine learning-based combined diagnostic accuracy of three types of quantitative indices obtained using dopamine transporter single-photon emission computed tomography (DAT SPECT)—specific binding ratio (SBR), putamen-to-caudate ratio (PCR)/fractal dimension (FD), and asymmetry index (AI)—for parkinsonian syndrome (PS). We also aimed to compare the effect of two different types of volume of interest (VOI) settings from commercially available software packages DaTQUANT (Q) and DaTView (V) on diagnostic accuracy. Methods: Seventy-one patients with PS and 40 without PS (NPS) were enrolled. Using SPECT images obtained from these patients, three quantitative indices were calculated at two different VOI settings each. SBR-Q, PCR-Q, and AI-Q were derived using the VOI settings from DaTQUANT, whereas SBR-V, FD-V, and AI-V were derived using those from DaTView. We compared the diagnostic value of these six indices for PS. We incorporated a support vector machine (SVM) classifier for assessing the combined accuracy of the three indices (SVM-Q: combination of SBR-Q, PCR-Q, and AI-Q; SVM-V: combination of SBR-V, FD-V, and AI-V). A Mann-Whitney U test and receiver-operating characteristics (ROC) analysis were used for statistical analyses. Results: ROC analyses demonstrated that the areas under the curve (AUC) for SBR-Q, PCR-Q, AI-Q, SBR-V, FD-V, and AI-V were 0.978, 0.837, 0.802, 0.906, 0.972, and 0.829, respectively. On comparing the corresponding quantitative indices between the two types of VOI settings, SBR-Q performed better than SBR-V (p = 0.006), whereas FD-V performed better than PCR-Q (p = 0.0003). No significant difference was observed between AI-Q and AI-V (p = 0.56). The AUCs for SVM-Q and SVM-V were 0.988 and 0.994, respectively; the two different VOI settings displayed no significant differences in terms of diagnostic accuracy (p = 0.48). Conclusion: The combination of the three indices obtained using the SVM classifier improved the diagnostic performance for PS; this performance did not differ based on the VOI settings and software used.

  • Access to Document (DOI)

• Quantitative evaluation of the tracer distribution in dopamine transporter SPECT for objective interpretation

  Iwabuchi Y., Nakahara T., Kameyama M., Yamada Y., Hashimoto M., Ogata Y., Matsusaka Y., Katagiri M., Itoh K., Osada T., Ito D., Tabuchi H., Jinzaki M.

  Annals of Nuclear Medicine (Annals of Nuclear Medicine)  32 ( 5 ) 363 - 371 2018.06

  ISSN  09147187

  　View Summary

  © 2018, The Japanese Society of Nuclear Medicine. Purpose: Quantification of the tracer distribution would add objectivity to the visual assessments of dopamine transporter (DAT) single photon emission computed tomography (SPECT) data. Our study aimed to evaluate the diagnostic utility of fractal dimension (FD) as a quantitative indicator of tracer distribution and compared with the conventional quantitative value: specific binding ratio (SBR). We also evaluated the utility of the combined index SBR/FD (SBR divided by FD). Materials and methods: We conducted both clinical and phantom studies. In the clinical study, 150 patients including 110 patients with Parkinsonian syndrome (PS) and 40 without PS were enrolled. In the phantom study, we used a striatal phantom with the striatum chamber divided into two spaces, representing the caudate nucleus and putamen. The SBR, FD, and SBR/FD were calculated and compared between datasets for evaluating the diagnostic utility. Mann–Whitney test and receiver-operating characteristics (ROC) analysis were used for analysis. Results: ROC analysis revealed that the FD value had high diagnostic performance [the areas under the curve (AUC) = 0.943] and the combined use of SBR and FD (SBR/FD) delivered better results than the SBR alone (AUC, 0.964 vs 0.899; p < 0.001). The sensitivity, specificity, and accuracy, respectively, were 79.1, 85.0, and 80.7% with SBR, 84.5, 97.5, and 88.0% with FD, and 92.7, 87.5, and 91.3% with SBR/FD. Conclusion: Our results confirmed that the FD value is a useful diagnostic index, which reflects the tracer distribution in DAT SPECT images. The combined use of SBR and FD was more useful than either used alone.

  • Access to Document (DOI)

• The psychological impact of disclosing amyloid status to Japanese elderly: A preliminary study on asymptomatic patients with subjective cognitive decline

  Wake T., Tabuchi H., Funaki K., Ito D., Yamagata B., Yoshizaki T., Kameyama M., Nakahara T., Murakami K., Jinzaki M., Mimura M.

  International Psychogeriatrics (International Psychogeriatrics)  30 ( 5 ) 635 - 639 2018.05

  ISSN  10416102

  　View Summary

  © 2018 International Psychogeriatric Association. In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.

  • Access to Document (DOI)

• The first report of a japanese case of seipinopathy with a BSCL2 N88S mutation

  Minami K., Takahashi S., Nihei Y., Oki K., Suzuki S., Ito D., Takashima H., Suzuki N.

  Internal Medicine (Internal Medicine)  57 ( 4 ) 613 - 615 2018

  ISSN  09182918

  　View Summary

  © 2018 The Japanese Society of Internal Medicine. Seipinopathy is an autosomal dominant neurodegenerative disease caused by mutations of the Berardinelli-Seip Congenital Lipodystrophy 2 (BSCL2) gene. We report the first Japanese case of seipinopathy with a heterozygous mutation of p.N88S in the BSCL2 gene. The patient showed bilateral hyperreflexia of the biceps, triceps, brachioradialis, and knee, as well as the pes cavus and distal dominant weakness and atrophy of both arms and legs, suggesting the involvement of both upper and lower motor neurons. Mutations of the BSCL2 gene have been known to cause motor neuron degeneration through endoplasmic reticulum stress. Seipinopathy should be considered in patients with symptoms mimicking amyotrophic lateral sclerosis.

  • Access to Document (DOI)

• RNA-binding proteins and the ALS/FTD pathological cascade.

  Ito D, Hatano M, Suzuki N

  Sci Transl Med. 9   415 2017.11

  Research paper (scientific journal), Joint Work, Accepted

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Establishment of ALS model by artificial RNA-binding proteins related to ALS proteinopathies

  Itō, Daisuke

  科学研究費補助金研究成果報告書 2020

• De novo design of cytoplasmic RNA-binding protein with prion-like domain related to ALS/FTD proteinopathies.

  Ito, Daisuke

  学事振興資金研究成果実績報告書 (慶應義塾大学)  2017

• Establishment of treatment target for ALS/FTLD

  Ito, Daisuke

  科学研究費補助金研究成果報告書 2017

• Utility of FDG-PET for diagnosis of preclinical Alzheimer's disease

  Ito, Daisuke

  科学研究費補助金研究成果報告書 2015

• Novel pathological pathway of ALS/FTLD-U

  Ito, Daisuke

  科学研究費補助金研究成果報告書 2013

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• Elucidation of molecular pathogenesis and establishment of therapeutic strategies for neurodegenerative diseases targeting microglia

  2021.04

  -

  2025.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

• Establishment of ALS model by artificial RNA-binding proteins related to ALS proteinopathies.

  2018.04

  -

  2021.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

• EEstablishment of treatment target for ALS / FTLD

  2015.04

  -

  2018.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• Japan Society for Dementia Research award

  2012.10, Japan Society for Dementia Research

• Sannshikai encouragement award

  2007.11

• 日本認知症学会学会賞

  2014.10, 日本認知症学会

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 三四会奨励賞

  2007

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

  2024

• LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

  2023

• LECTURE SERIES, INTERNAL MEDICINE

  2023

• PHYSICAL ASSESSMENT

  2022

• LECTURE SERIES, INTERNAL MEDICINE (NEUROLOGY)

  2022

display all >>